http://bit.ly/2FJa4X9
"We are pleased with the safety profile to date and early efficacy
signals of MDNA55. We are amending the protocol at the recommendation of
our clinical advisors to further improve the chances for demonstrating
increased therapeutic benefit for patients living with this
life-threatening disease," said Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna.
Principal Investigator, John H. Sampson MD, PhD, of Duke University
Medical Center Department of Neurosurgery, commented, "The study has
contributed substantially to the improvement of Convection Enhanced
Delivery of drugs directly into brain tumors. More importantly, we are
seeing definite biological effects of MDNA55 in some patients as we
await final study results to see whether these translate into robust
longer term benefits."
"We have used the occasion of this recruitment milestone to implement optimal methodologies in the amended protocol," commented Martin Bexon MD, Head of Clinical Development. "With the experience gleaned from the ongoing Phase 2b
clinical trial of MDNA55 in rGBM, we are able, for instance, to allow
for more personalized dosing based on the tumor load and incorporate
advanced imaging modalities to measure treatment responses more
reliably, despite significant changes due to necrosis and
inflammation." Additionally, the amendment will allow investigators to
administer a second dose of MDNA55 where appropriate.
Thanks to Al Musella for this link, which he posted on a Brain Tumor News Blast today:
ReplyDeletehttps://www.prnewswire.com/news-releases/medicenna-presents-promising-clinical-data-from-phase-2b-recurrent-glioblastoma-trial-of-mdna55-300791451.html
The trick is, how does one get testing for IL4R before deciding whether to join this trial or not?
Delete